TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30627959

Group type: EXPERIMENTAL
Intervention: Randomised clinical trials in obstetrics
Number of subjects: 9967
Study: 29768709

Group type: EXPERIMENTAL
Intervention: IMQ (5 mg) applied once daily for 72 hours under occlusion to tape stripped skin (n = 8)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: IMQ (5 mg) applied once daily for 72 hours under occlusion to intact skin (n = 8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 16
Study: 26500351

Group type: EXPERIMENTAL
Intervention: Tafenoquine (50, 100, 300, or 600 mg) plus chloroquine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chloroquine plus primaquine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chloroquine alone
Number of subjects: 0
Study: 24268371

Group type: COMPARATOR
Intervention: Standard 14-day quadruple treatment (Rabeprazole 20mg-bid, bismuth subcitrate 120 mg-qid, Tetracycline 500 mg-qid, Metronidazole 500 mg-tid for 2 weeks)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 10-day sequential therapy (20 mg rabeprazole and 1g amoxicillin twice daily for the first 5 days, followed by standard quadruple treatment for the remaining 5 days)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 12-day sequential therapy (20 mg rabeprazole and 1g amoxicillin twice daily for the first 5 days, followed by standard quadruple treatment for the remaining 7 days)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 14-day sequential therapy (20 mg rabeprazole and 1g amoxicillin twice daily for the first 5 days, followed by standard quadruple treatment for the remaining 9 days)
Number of subjects: 160
Study: 22507748

Group type: EXPERIMENTAL
Intervention: Daily supplementation with iron (60-120mg) plus folic acid (0.4mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Weekly supplementation with 120mg iron plus various amounts of folic acid
Number of subjects: 100
Study: 20199521

Group type: EXPERIMENTAL
Intervention: Rufinamide (25-60 mg/kg/day)
Number of subjects: 124
Study: 17664149

Group type: EXPERIMENTAL
Intervention: Vitamin C (1 g intravenous infusion)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 16225161

Group type: EXPERIMENTAL
Intervention: MR carbonyl iron (45 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ferrous fumarate (300 mg)
Number of subjects: 60
Study: 11818358

Group type: EXPERIMENTAL
Intervention: Family physicians (FPs) recruitment
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: Seniors recruitment
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: Seniors refusal rates
Number of subjects: 889
Study: 9806669

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) at 12.5 ng x kg(‐1) x min(‐1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 7631683

Group type: EXPERIMENTAL
Intervention: Iron prophylaxis
Number of subjects: 2693

Group type: COMPARATOR
Intervention: Iron only if needed
Number of subjects: 2693
Study: 2575987

Group type: EXPERIMENTAL
Intervention: epanolol
Number of subjects: 211

Group type: COMPARATOR
Intervention: metoprolol
Number of subjects: 211
Study: 333957

Group type: EXPERIMENTAL
Intervention: Group A (relaxation response technique)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Group B (sit quietly)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Group C (no instructions)
Number of subjects: 126
Study: 7323701

Group type: EXPERIMENTAL
Intervention: End-to-side jejunoileostomy
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: End-to-end jejunoileostomy
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Gastric bypass
Number of subjects: 26

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 26
Study: 31592939

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (1.6 × 10 colony‐forming units of Lactobacillus rhamnosus capsules)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo control (maltodextrin capsules)
Number of subjects: 44
Study: 29425140

Group type: EXPERIMENTAL
Intervention: Nature slideshow
Number of subjects: 58

Group type: COMPARATOR
Intervention: Urban slideshow
Number of subjects: 58

Group type: COMPARATOR
Intervention: No distractions (control group)
Number of subjects: 58
Study: 26781763

Group type: EXPERIMENTAL
Intervention: Vitamin D (1000 IU) and Evening Primrose Oil (1000 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 25401501

Group type: EXPERIMENTAL
Intervention: Serum selenium deficiency (<85 μg/L) pre-ART
Number of subjects: 0

Group type: COMPARATOR
Intervention: Third quartile serum selenium (74.86-95.10 μg/L)
Number of subjects: 0
Study: 22863643

Group type: EXPERIMENTAL
Intervention: Myofascial release therapy + Kinesiotherapy
Number of subjects: 65
Study: 19781696

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17376037

Group type: EXPERIMENTAL
Intervention: Transnasal EGD
Number of subjects: 124

Group type: COMPARATOR
Intervention: Peroral EGD
Number of subjects: 124
Study: 16320441

Group type: EXPERIMENTAL
Intervention: 12-step practices (number of meetings attended, prescribed activities engaged)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Specific 12-step activities (having a sponsor, doing service)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Service work in AA and/or Narcotics Anonymous
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Higher proportion of abstinent individuals in the social network
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: 12-step measures thresholds (e.g., >20 meetings for alcoholics, 2 or more nondrinkers in the social network)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Ongoing 12-step involvement (sponsor and meetings)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Doing service
Number of subjects: 302
Study: 12221027

Group type: EXPERIMENTAL
Intervention: Checkpoint Program (intervention group receiving persuasive communications)
Number of subjects: 452

Group type: COMPARATOR
Intervention: General information about driving safety (comparison group)
Number of subjects: 452
Study: 10212042

Group type: EXPERIMENTAL
Intervention: Immunoadsorption (IA)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Plasma exchange (PE)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Both IA and PE
Number of subjects: 44
Study: 7840170

Group type: EXPERIMENTAL
Intervention: Epinephrine infusion
Number of subjects: 7

Group type: COMPARATOR
Intervention: Saline infusion (Control)
Number of subjects: 7
Study: 2090834

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0
Study: 674624

Group type: EXPERIMENTAL
Intervention: 3 g iopanoic acid administered over 6 hours (0.5 g/hour)
Number of subjects: 168

Group type: COMPARATOR
Intervention: 3 g iopanoic acid administered in a single dose
Number of subjects: 168
Study: 31088784

Group type: EXPERIMENTAL
Intervention: Headgear (HG)
Number of subjects: 2766

Group type: COMPARATOR
Intervention: No headgear (NoHG)
Number of subjects: 2766
Study: 29396205

Group type: EXPERIMENTAL
Intervention: DM + PAD
Number of subjects: 62

Group type: COMPARATOR
Intervention: DM without PAD
Number of subjects: 62
Study: 27295465

Group type: EXPERIMENTAL
Intervention: Media coverage of wise interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cautious language introduced to media coverage
Number of subjects: 0
Study: 23682041

Group type: EXPERIMENTAL
Intervention: Colorectal endocoil (CEC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Prostate endocoil (PEC)
Number of subjects: 30
Study: 23869842

Group type: EXPERIMENTAL
Intervention: Overweight or obese before stroke
Number of subjects: 3173

Group type: EXPERIMENTAL
Intervention: Underweight before stroke
Number of subjects: 3173

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus before stroke
Number of subjects: 3173

Group type: EXPERIMENTAL
Intervention: Current smoking before stroke
Number of subjects: 3173

Group type: EXPERIMENTAL
Intervention: Physical inactivity before stroke
Number of subjects: 3173

Group type: EXPERIMENTAL
Intervention: Lowest physical function quartile before stroke
Number of subjects: 3173

Group type: EXPERIMENTAL
Intervention: Current hormone use before stroke
Number of subjects: 3173
Study: 20625738

Group type: EXPERIMENTAL
Intervention: Sorafenib and erlotinib treatment
Number of subjects: 23
Study: 18928103

Group type: EXPERIMENTAL
Intervention: Buzhong Yiqi Pill (BYP) combined with imodium
Number of subjects: 80

Group type: COMPARATOR
Intervention: Imodium (loperamide hydrochloride)
Number of subjects: 80
Study: 15920209

Group type: EXPERIMENTAL
Intervention: Video plus interview
Number of subjects: 197

Group type: COMPARATOR
Intervention: Brochure plus interview
Number of subjects: 197

Group type: COMPARATOR
Intervention: Routine preanesthetic interview
Number of subjects: 197
Study: 12794408

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure at 0 cm H(2)O
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure at 5 cm H(2)O
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure at 10 cm H(2)O
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Spontaneous breathing with 0 cm H(2)O continuous positive airway pressure
Number of subjects: 12
Study: 10934092

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension via face mask 0.25 mg daily
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension via face mask 0.25 mg twice daily
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension via face mask 0.5 mg twice daily
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension via mouthpiece 0.25 mg twice daily
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension via mouthpiece 1.0 mg daily
Number of subjects: 481

Group type: COMPARATOR
Intervention: Budesonide inhalation suspension via face mask or mouthpiece
Number of subjects: 481
Study: 8939176

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium pretreatment
Number of subjects: 8
Study: 8240462

Group type: EXPERIMENTAL
Intervention: Garlic-ginkgo combination product (Allium plus)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 3816230

Group type: EXPERIMENTAL
Intervention: RU486 + 1 mg PG pessary
Number of subjects: 39

Group type: COMPARATOR
Intervention: RU486 alone
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: RU486 + 2 mg Gemeprost
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: RU486 + PG
Number of subjects: 39
Study: 30208854

Group type: EXPERIMENTAL
Intervention: Group 1 intervention: physical activity assessment during Nephrology clinical visit, brief counseling at pre-dialysis education, and physical activity wearable.
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Group 2 intervention: Group 1 components plus a referral to a free, EIM practitioner-led group exercise program over 16 weeks (8-week core intervention; 8-week follow up).
Number of subjects: 96
Study: 27472949

Group type: EXPERIMENTAL
Intervention: Tribendimidine 25 mg
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Tribendimidine 50 mg
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Tribendimidine 100 mg
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Tribendimidine 200 mg
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Tribendimidine 200 mg (four 50 mg tablets)
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Tribendimidine 400 mg
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Tribendimidine 600 mg
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Tribendimidine 50 mg (children)
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Tribendimidine 100 mg (children)
Number of subjects: 446
Study: 23774460

Group type: EXPERIMENTAL
Intervention: Anemia (mild)
Number of subjects: 9687

Group type: EXPERIMENTAL
Intervention: Anemia (moderate-to-severe)
Number of subjects: 9687

Group type: COMPARATOR
Intervention: No anemia
Number of subjects: 9687
Study: 22178258

Group type: COMPARATOR
Intervention: Low carbohydrate breakfast (LCb)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: High carbohydrate and protein breakfast (HCPb)
Number of subjects: 193
Study: 20736298

Group type: EXPERIMENTAL
Intervention: Lapatinib (1,250 mg/day) plus capecitabine (2,000 mg/m2)
Number of subjects: 399

Group type: COMPARATOR
Intervention: Capecitabine monotherapy (2,500 mg/m2)
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Lapatinib plus capecitabine (considering crossover)
Number of subjects: 399
Study: 18174476

Group type: EXPERIMENTAL
Intervention: rFVIIa (3H group)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: rFVIIa (4H group)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study: 15836977

Group type: EXPERIMENTAL
Intervention: Short-term opioid administration in chronic pain patients
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Long-term opioid administration in chronic pain patients
Number of subjects: 4

Group type: COMPARATOR
Intervention: Pain-free control subjects
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Chronic non-malignant pain subjects
Number of subjects: 4
Study: 12740447

Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 10494053

Group type: EXPERIMENTAL
Intervention: Standard pressure differential valves
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Delta valves
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Orbis Sigma valves
Number of subjects: 344

Group type: COMPARATOR
Intervention: Control group (last quarter patients)
Number of subjects: 344
Study: 9063208

Group type: EXPERIMENTAL
Intervention: Supplemental irrigation with 15 mL of a 100‐mg/mL tetracycline solution
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tetracycline‐loaded fiber after mechanical instrumentation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Supragingival and subgingival scaling with an ultrasonic scaler (Control)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All three treatment modalities
Number of subjects: 12
Study: 1891488

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine substitution with behavioral therapy
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine substitution (nicotine patches)
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Behavioral therapy
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Individual versus fixed dose of nicotine patches
Number of subjects: 403
Study: 6382936

Group type: EXPERIMENTAL
Intervention: iohexol 300 mg I/ml
Number of subjects: 50

Group type: COMPARATOR
Intervention: meglumine iothalamate 280 mg I/ml
Number of subjects: 50
Study: 31658293

Group type: EXPERIMENTAL
Intervention: 10 ml dye injection
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 30 ml dye injection
Number of subjects: 7
Study: 30002088

Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of 0.5 mL 0.1% nitroglycerin
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study: 26698408

Group type: COMPARATOR
Intervention: HABIT (bimanual therapy)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: HABIT + Tactile training (HABIT+T)
Number of subjects: 20
Study: 25179038

Group type: EXPERIMENTAL
Intervention: Disposable ECG lead wires
Number of subjects: 51
Study: 22169884

Group type: EXPERIMENTAL
Intervention: 10 mg methylphenidate
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 20 mg methylphenidate
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 40 mg methylphenidate
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 20709727

Group type: EXPERIMENTAL
Intervention: Participation in a daylong group smoking cessation workshop
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cox proportional hazard modeling
Number of subjects: 45
Study: 17334548

Group type: EXPERIMENTAL
Intervention: Saline solution during surgery (Group SS)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil during surgery (Group 5-FU1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil with multiple injections (Group 5-FU3)
Number of subjects: 50
Study: 15750368

Group type: EXPERIMENTAL
Intervention: CV4
Number of subjects: 20

Group type: COMPARATOR
Intervention: CV4 sham
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study: 11874443

Group type: EXPERIMENTAL
Intervention: Thiazolidinediones (troglitazone)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (MET added to SU monotherapy)
Number of subjects: 28
Study: 10468751

Group type: EXPERIMENTAL
Intervention: Specific dietary regimen recommended and corrected according to a comprehensive metabolic evaluation (Group 1)
Number of subjects: 242

Group type: COMPARATOR
Intervention: General dietary measures with minimal metabolic screening (Group 2)
Number of subjects: 242
Study: 8688984

Group type: EXPERIMENTAL
Intervention: Dorzolamide
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Pilocarpine
Number of subjects: 92
Study: 1282609

Group type: EXPERIMENTAL
Intervention: NIT (nitrates) 80-120 mg/day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: NIF (nifedipine) 40-60 mg/day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: NIS (nisoldipine) 10-20 mg/day
Number of subjects: 30
Study: 6428511

Group type: EXPERIMENTAL
Intervention: Terbutaline 1 mg/day (subcutaneous, continuous infusion or injections every six hours)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Terbutaline 12 mg/day (subcutaneous, continuous infusion)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo (subcutaneous, continuous infusion or injections every six hours)
Number of subjects: 4
Study: 31509028

Group type: EXPERIMENTAL
Intervention: RRx‐001 followed by four cycles of a platinum doublet, and then alternating cycles of RRx‐001 and single agent platinum until progression
Number of subjects: 120

Group type: COMPARATOR
Intervention: Platinum doublet
Number of subjects: 120
Study: 29402815

Group type: EXPERIMENTAL
Intervention: Topical pharyngeal surface anesthesia
Number of subjects: 11

Group type: COMPARATOR
Intervention: No anesthesia
Number of subjects: 11
Study: 26502371

Group type: EXPERIMENTAL
Intervention: ALA treatment in donor and recipient (DR group)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Recipient ALA treatment
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 26
Study: 25329228

Group type: EXPERIMENTAL
Intervention: EPA-enriched supplementation (2.2 g EPA)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard isocaloric supplementation
Number of subjects: 69
Study: 22265753

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (8-week MBCT-based eating intervention)
Number of subjects: 26
Study: 20014183

Group type: EXPERIMENTAL
Intervention: Milk thistle (MT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 18550438

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SERT gene promoter polymorphism 5‐HTTLPR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SERT expression in intestinal mucosa
Number of subjects: 0
Study: 16172356

Group type: EXPERIMENTAL
Intervention: Atomized nasal douche
Number of subjects: 200

Group type: COMPARATOR
Intervention: Nasal lavages with isotonic sodium chloride solution
Number of subjects: 200
Study: 12154423

Group type: EXPERIMENTAL
Intervention: tranexamic acid
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: aprotinin
Number of subjects: 18

Group type: COMPARATOR
Intervention: control group
Number of subjects: 18
Study: 9493671

Group type: EXPERIMENTAL
Intervention: Daytime mechanical ventilation (dMV)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Nocturnal mechanical ventilation (nMV)
Number of subjects: 34
Study: 7536072

Group type: EXPERIMENTAL
Intervention: G-CSF 5 micrograms/kg sc daily for 8 days and G-CSF 16 micrograms/kg i.v. four times daily after autologous BMT
Number of subjects: 44

Group type: COMPARATOR
Intervention: GM-CSF (250 micrograms/m2 sc daily for 8 days or 125 micrograms/m2 sc twice daily for 8 days) and GM-CSF (250 micrograms/m2 i.v. four times daily) after autologous BMT
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: G-CSF after autologous BMT
Number of subjects: 44
Study: 3299684

Group type: EXPERIMENTAL
Intervention: Synovectomy (n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No synovectomy (n = 15)
Number of subjects: 30
Study: 31995222

Group type: EXPERIMENTAL
Intervention: Mother's hug
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control
Number of subjects: 135
Study: 28783871

Group type: EXPERIMENTAL
Intervention: Ozanimod (escalated from 0.25 to 2 mg over 14 days)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo (for 14 days)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg (administered on days 2 and 17)
Number of subjects: 124
Study: 27599229

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing with Standard Management of Depression (MI-SMD)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Standard Management of Depression (SMD) alone
Number of subjects: 168
Study: 24549027

Group type: EXPERIMENTAL
Intervention: Healthy Nordic diet (ND) rich in whole-grain rye and wheat, n=96
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control diet, n=70
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Healthy Nordic diet (ND)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Total plasma AR concentration
Number of subjects: 166
Study: 23073583

Group type: EXPERIMENTAL
Intervention: 20 Hz rTMS
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: TBS rTMS
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 10 Hz rTMS
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 80
Study: 20535041

Group type: EXPERIMENTAL
Intervention: Monosegmental transpedicular fixation
Number of subjects: 85

Group type: COMPARATOR
Intervention: Biosegmental transpedicular fixation
Number of subjects: 85
Study: 18958837

Group type: EXPERIMENTAL
Intervention: Insulin therapy (including glucose-insulin-potassium (GIK) approaches and non-GIK approaches)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin therapy in critically ill non-ACS patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ongoing and planned trials of insulin in ACS patients
Number of subjects: 0